China Post Securities released a research report on April 26 stating that it gave Haier Biotech (688139.SH) a purchase rating. The main reasons for the rating include: 1) 2024Q1 achieved positive year-on-year growth in performance, with rapid month-on-month growth; 2) continuous improvement of non-storage products to support rapid growth in new industries; 3) strong infrastructure and recovery to promote the integrated development of the life science and medical innovation sector; 4) domestic market sinking, and the backlog of foreign projects is expected to gradually transform. (Mainichi Keizai Shimbun)
中邮证券4月26日发布研报称，给予海尔生物（688139.SH）买入评级。评级理由主要包括：1）2024Q1实现业绩同比正增长，环比高速增长；2）非存储产品持续完善，创新支持新产业高速增长；3）基建与复苏发力推动生命科学与医疗创新板块齐发展；4）国内推动市场下沉，国外积压项目有望逐步转化。（每日经济新闻）
China Post Securities released a research report on April 26 stating that it gave Haier Biotech (688139.SH) a purchase rating. The main reasons for the rating include: 1) 2024Q1 achieved positive year-on-year growth in performance, with rapid month-on-mon
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.